Nasopharyngeal Viral Load Is the Major Driver of Incident Antibody Immune Response to SARS-CoV-2 Infection.

"Potential conflicts of interest. M.X., K.-C.C., B.H., and B.J.M. are Regeneron Pharmaceuticals, Inc., employees/shareholders and report grants from BARDA. M.P.O. and G.A.H. are Regeneron Pharmaceuticals, Inc., employees/stockholders who report having a patent pending, which has been licensed and for which they are receiving royalties, with Regeneron Pharmaceuticals, Inc., as well as a pending patent application, and report grants from BARDA. A.T.H. is a Regeneron Pharmaceuticals, Inc., employee/stockholder and a Pfizer stockholder and has a patent pending, which has been licensed and for which they are receiving royalties, with Regeneron Pharmaceuticals, Inc., and reports grants from BARDA. E.F.-N. was an employee of and holds stocks and shares in Regeneron Pharmaceuticals, Inc., and reports having a patent pending, which has been licensed and for which they are receiving royalties, with Regeneron Pharmaceuticals, Inc., as well as a pending patent application, and reports grants from BARDA. F.I. and J.D.H. are Regeneron Pharmaceuticals, Inc., employees/stockholders who report having a patent pending, which has been licensed and for which they are receiving royalties, with Regeneron Pharmaceuticals, Inc., and report grants from BARDA. P.H. is a former Regeneron Pharmaceuticals, Inc., employee and current stockholder and reports grants from BARDA. M.A.M. reports being an employee of the federal government, which, as part of USG, through Operation Warp Speed, supported the clinical trial network involved in implementation of this effort. M.S.C. reports a relationship with the National Institutes for Health for study funding and Regeneron Pharmaceuticals, Inc., for drug studies; reports receiving consulting fees from Aerium for a Scientific Advisory Board and Atrea for a Medical Advisory Board; reports receiving payment for lectures from NY Course, MJH Life Sciences, Clinical Care Solutions, Virology Education, Amgen, Medscape, and UpToDate; reports receiving payment for an educational panel from AstraZeneca and GSK; reports receiving support for attending meetings with Krog Healthcare-GSK and Trinity Health Sciences; and has a leadership role for the HIV Prevention Trials Network, COVID-19 Prevention Network."

"Financial support. This study was supported by Regeneron Pharmaceuticals, Inc., and F. Hoffmann-La Roche Ltd. This trial was conducted jointly with the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institutes of Health (NIH). The COVID-19 Prevention Network (CoVPN) was supported by cooperative agreement awards from the NIAID and NIH. The work on this study was supported by award numbers UM1AI068619 and UM1AI148684. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Certain aspects of this project have been funded in whole or in part with federal funds from the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under OT number HHSO100201700020C. Financial support ."